Consensus LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
9.32 ^USD	+0.22%		-25.50%	+12.42%

May. 09	Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	MT
May. 08	Transcript : LifeMD, Inc., Q1 2024 Earnings Call, May 08, 2024

Evolution of the average Target Price on LifeMD, Inc.

Price target over the last 5 years

History of analyst recommendation changes

447bee6fd5277d05a344d1cd9.OGV23wVMi_hyJdUmDZqXKJYc03PcSGsHkrm0k8pGuHI.AUhAuHI7prQZdr5NdPHOXslKix7xJVNG6O7D1qsx8AVLXCSbcxSmsT1ngA~22a29449e2e62654ffa95501adc83511

Analyst Recommendations on LifeMD, Inc.

Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	May. 09	MT
BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	Apr. 23	MT
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	Mar. 12	MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	Mar. 12	MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	Mar. 12	MT
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	Jan. 11	MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	Nov. 14	MT
HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	Nov. 09	MT
B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	Nov. 09	MT
Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	23-10-02	MT
Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	23-07-21	MT
B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	23-07-10	MT
HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	23-07-03	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23-03-23	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23-03-23	MT
B. Riley Lowers LifeMD's Price Target to $8 from $16, Notes Slower-than-Anticipated Start in Q1 Impacted by Technology Upgrades, Integrations; Keeps Buy Rating	22-05-16	MT
BTIG Adjusts LifeMD's Price Target to $15 From $30, Reiterates Buy Rating	21-11-11	MT
LIFEMD : BTIG Research Adjusts LifeMD Price Target to $30 From $35, Maintains Buy Rating	21-08-13	MT
LIFEMD : BTIG Adjusts LifeMD's Price Target to $35 From $40, Reiterates Buy Rating	21-07-19	MT
CONVERSION LABS : B. Riley Starts Conversion Labs at Buy With $35 Price Target	21-02-05	MT
CONVERSION LABS : BTIG Starts Conversion Labs at Buy With $15 Price Target	21-01-07	MT